


RealRate

PHARMACEUTICAL 2017

MyoKardia Inc. Rank 44 of 313





PHARMACEUTICAL 2017



MyoKardia Inc. Rank 44 of 313

The relative strengths and weaknesses of MyoKardia Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyoKardia Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 164% points. The greatest weakness of MyoKardia Inc. is the variable Revenues, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 499% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	186,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,988
Liabilities, Non-Current	436
Other Assets	12,285
Other Compr. Net Income	8.0
Other Expenses	0
Other Liabilities	22,500
Other Net Income	39,352
Property and Equipment	2,758
Research and Development	36,215
Revenues	0
Selling, General and Administrative Expense	16,289

Output Variable	Value in 1000 USD
Assets	201,306
Liabilities	55,924
Expenses	52,504
Stockholders Equity	145,382
Net Income	-13,152
Comprehensive Net Income	-13,148
Economic Capital Ratio	83%